We utilize next general AI tools and agentic workflows to drive hyper-intelligent target selection.
We build and use state of the art deep learning models combined with the rules of chemistry and physics to generate and optimize de-novo medicines.
Designing and optimizing antibodies and nanobodies.
Generation of de-novo small molecules.
Exploring and building therapies in the emerging space of siRNA.
Utilizing the complimentary nature of different therapeutic approaches.
We are building an AI-powered, interconnected global network of industry leaders and seminal health centers.